Antirotinib Hydrochloride Plus Whole Brain Radiotherapy for Small Cell Lung Cancer With Brain Metastases

Phase 2Active Not RecruitingNCT06611657

Cancer Institute and Hospital, Chinese Academy of Medical Sciences40 enrolled

Overview

The objective of this study was to evaluate the efficacy and safety of whole brain radiotherapy combined with antirotinib hydrochloride in the treatment of brain metastases in small cell lung cancer

This was a single-center, single-arm trail. Enrolled patients were pathologically diagnosed with small cell lung cancer and had completed at least 4 cycles of first-line chemotherapy. Patients with brain metastases at first visit or during treatment were treated with whole brain radiotherapy combined with anlotinib hydrochloride. Oral antirotinib was started 2 weeks before radiotherapy for brain metastases and stopped for 1 week after 2 weeks. After radiotherapy, antirotinib was continued until tumor progression. Efficacy and toxicity data were collected for evaluation and analysis.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Whole Brain Radiotherapy

Interventions

Antirotinib hydrochlorideDRUG

Oral antirotinib treatment was started 2 weeks before radiotherapy for brain metastases, stopped for 1 week after 2 weeks, and continued after radiotherapy until tumor progression

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Small cell lung cancer confirmed by pathology, completion of at least 4 cycles of first-line chemotherapy, and measurable disease according to RECIST criteria. 2. The expected survival time is more than 3 months. 3. Intracranial metastases ≤10. 4. Adequate organ and bone marrow function. Exclusion Criteria: 1. Patients who have used antiangiogenic drugs within the previous 1 month. 2. Non-small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer). 3. Small cell lung cancer with hilar invasion or hemoptysis. 4. Patients with intracranial acute, subacute cerebral infarction, intracranial lesions acute, subacute hemorrhage. 5. An unresolved acute toxic reaction period higher than grade 2 of CTC-AE(4.0) due to any prior treatment. 6. Advanced patients with severe symptoms, tumors that have spread to the internal organs, and a short-term risk of life-threatening complications. 7. Patients with life-threatening conditions of other severe and/or uncontrolled diseases.

Locations (1)

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

Intracranial progression-free survival

Time from enrollment to intracranial tumor progression or death

Time frame: 6 months

Secondary Outcomes

Overall Survival

The time from enrollment to death from any cause was calculated as the time of death. For participants who were lost to follow-up, the time of death was usually the time of the last follow-up.

Time frame: 1 year

progression-free survival

The time from enrollment to tumor progression (any aspect) or death from any cause

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.